Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug Resistant HIV-2 Infection

Antoine Bachelard,Quentin Le Hingrat,Valentine-Marie Ferre,Minh Le,Gilles Peytavin,Florence Damond,Charlotte Charpentier, Guillemette Fremont Goudot,Jeanne Goupil de Bouille, Sylvie Lariven,Pierre Delobel,Yazdan Yazdanpanah,Diane Descamps,Sophie Matheron,Jade Ghosn

CLINICAL INFECTIOUS DISEASES（2024）

引用 0|浏览12

暂无评分

摘要

We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.

查看译文

关键词

HIV-2,salvage therapy,ibalizumab,multi-drug resistance,foscarnet

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要